Pfizer Inc. and BioNTech said a large-scale clinical trial has shown their COVID-19 vaccine is safe and produced strong antibody responses in children aged five to 11.

In a news release issued Monday, Pfizer said it will be submitting the results to the FDA, EMA, and other regulatory agencies around the world as soon as possible.

For elementary school-aged kids, Pfizer tested a much lower dose in elementary school-aged children — a third of the amount that’s in each shot given now.

The vaccine is already available for anyone 12 and older in the U.S., Canada, and across the globe.

Pfizer said children in the five to 11 age group developed coronavirus-fighting antibody levels just as strong as teenagers and young adults following their second dose.